Related Experiment Video

Updated: Jul 19, 2026

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

[Clinical significance of cyclin Dl expression in non-small cell lung cancer]

Dorota Dworakowska1

  • 1Klinika Chorób Wewnqtrznych, Endokrynologii i Zaburzeń Hemostazy, AM w Gdańsku. ddw@amg.gda.pl

Pneumonologia I Alergologia Polska
|September 23, 2006
PubMed

Insights

Genetic alterations in non-small cell lung cancer (NSCLC) are crucial. The CCND1 gene

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Context:

  • Non-small cell lung cancer (NSCLC) presents complex genetic alterations.
  • The CCND1 gene, encoding cyclin D1, plays a role in cell cycle regulation.
  • CCND1 amplification and cyclin D1 overexpression are observed in various cancers, often linked to poor prognosis.

Purpose:

  • To investigate the clinical significance of CCND1 gene amplification and expression in NSCLC.
  • To clarify the controversial prognostic value of CCND1 alterations in NSCLC.

Summary:

  • CCND1 gene amplification and cyclin D1 overexpression are implicated in NSCLC.
  • The prognostic value of these CCND1 alterations in NSCLC is currently debated.
  • Further research is needed to establish the clinical significance of CCND1 in NSCLC.

Impact:

  • Potential to identify novel biomarkers for NSCLC prognosis.
  • May contribute to a better understanding of NSCLC pathogenesis.
  • Could inform future therapeutic strategies targeting CCND1 in NSCLC.

Related Concept Videos

Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...